The Effect of Remifentanil Infusion During Emergence on the Incidence of Emergence Delirium
Primary Purpose
Delirium
Status
Unknown status
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Remifentanil
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Delirium
Eligibility Criteria
Inclusion Criteria:
- American Society of Anesthesiologists physical status I and II
- preschool-aged children undergoing strabismus surgery
Exclusion Criteria:
- psychological disorders
- emotional disorders
- abnormal cognitive development
- developmental delay
- allergy to the drugs in our protocol
Sites / Locations
- Department of Anesthesiology and Pain Medicine, Yeungnam University hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
remifentanil group
control
Arm Description
Remifentanil 0.05 ug/kg/min is infused to the patients.
Normal saline 0.2 ml/kg/hour is infused to the patients
Outcomes
Primary Outcome Measures
the scale of emergence agitation
A blinded observer record emergence agitation at just after laryngeal mask removal, 5 minutes after arrival in postanesthetic care unit, 10 minutes after arrival in postanesthetic care unit, 15 minutes after arrival in postanesthetic care unit, 30 minutes after arrival in postanesthetic care unit, and 30 minutes after discharge from postanesthetic care unit.
Secondary Outcome Measures
the effect of remifentanil on the emergence
A blinded observer record duration of anaesthesia, eye-opening time, time to remove laryngeal mask airway, respiratory depression, nausea, and vomiting at the end of surgery, 5 minutes after arrival in postanesthetic care unit, 10 minutes after arrival in postanesthetic care unit, 15 minutes after arrival in postanesthetic care unit, 30 minutes after arrival in postanesthetic care unit, and 30 minutes after discharge from postanesthetic care unit.
Full Information
NCT ID
NCT02108795
First Posted
March 31, 2014
Last Updated
July 14, 2015
Sponsor
Yeungnam University College of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02108795
Brief Title
The Effect of Remifentanil Infusion During Emergence on the Incidence of Emergence Delirium
Official Title
The Effect of Remifentanil Infusion During Emergence on the Incidence of Emergence Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Unknown status
Study Start Date
April 2014 (undefined)
Primary Completion Date
April 2016 (Anticipated)
Study Completion Date
May 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Yeungnam University College of Medicine
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the present study is to assess the effect of postoperative remifentanil infusion on the incidence of emergence agitation in preschool-aged children undergoing strabismus surgery with sevoflurane anaesthesia.
Detailed Description
Patients are randomly assigned to one of two groups. Anesthesia is maintained with sevoflurane and remifentanil infusion. All patients received a predetermined concentrations of remifentanil according to their group assignments (control group, remifentanil 0 ug/kg/min; remifentanil group, remifentanil 0.05 ug/kg/min) from 10 minutes before the end of surgery to discharge from postanesthetic care unit. emergence agitation is assessed during the emergence phase.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Delirium
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
86 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
remifentanil group
Arm Type
Experimental
Arm Description
Remifentanil 0.05 ug/kg/min is infused to the patients.
Arm Title
control
Arm Type
Placebo Comparator
Arm Description
Normal saline 0.2 ml/kg/hour is infused to the patients
Intervention Type
Drug
Intervention Name(s)
Remifentanil
Other Intervention Name(s)
remifentanil (ultiva)
Intervention Description
Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
the scale of emergence agitation
Description
A blinded observer record emergence agitation at just after laryngeal mask removal, 5 minutes after arrival in postanesthetic care unit, 10 minutes after arrival in postanesthetic care unit, 15 minutes after arrival in postanesthetic care unit, 30 minutes after arrival in postanesthetic care unit, and 30 minutes after discharge from postanesthetic care unit.
Time Frame
up to 30 minutes after arrival in postanesthetic care unit, and 30 minutes after discharge from postanesthetic care unit.
Secondary Outcome Measure Information:
Title
the effect of remifentanil on the emergence
Description
A blinded observer record duration of anaesthesia, eye-opening time, time to remove laryngeal mask airway, respiratory depression, nausea, and vomiting at the end of surgery, 5 minutes after arrival in postanesthetic care unit, 10 minutes after arrival in postanesthetic care unit, 15 minutes after arrival in postanesthetic care unit, 30 minutes after arrival in postanesthetic care unit, and 30 minutes after discharge from postanesthetic care unit.
Time Frame
up to 30 minutes after the discharge form postanesthetic care unit
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
7 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
American Society of Anesthesiologists physical status I and II
preschool-aged children undergoing strabismus surgery
Exclusion Criteria:
psychological disorders
emotional disorders
abnormal cognitive development
developmental delay
allergy to the drugs in our protocol
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sangjin Park, M.D.
Phone
82-53-620-3366
Email
apsj0718@naver.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sangjin Park, M.D.
Organizational Affiliation
Department of Anesthesiology and Pain Medicine, College of medicine, Yeungnam University, Daemyung-Dong, Nam-Gu, Daegu, Republic of Korea
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Anesthesiology and Pain Medicine, Yeungnam University hospital
City
Daegu
ZIP/Postal Code
705-035
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Duckhee Lee, M.D.
Phone
82-53-620-3365
Email
apsj0718@naver.com
First Name & Middle Initial & Last Name & Degree
Sangjin Park, M.D.
12. IPD Sharing Statement
Learn more about this trial
The Effect of Remifentanil Infusion During Emergence on the Incidence of Emergence Delirium
We'll reach out to this number within 24 hrs